Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

Innovent Starts China Trials of Bi-Specific Wet AMD Treatment

publication date: Apr 18, 2019

Innovent Biologics has dosed the first patient in a China Phase I trial of IBI302, a novel bi-specific fusion protein aimed at treating wet age-related macular degeneration (wet AMD). IBI302 targets vascular endothelial growth factor A (VEGF-A), the current standard of care, along with complement proteins that regulate the production of VEGF. Michael Yu, Founder and CEO of Innovent, said IBI302 may improve wet AMD treatment, offering a less-frequent dosing regimen and better long-term outcomes because the candidate treats causes rather than effects of the disease. More details....

Stock Symbol: (HK: 01801)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.